TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intensive Nutrition in Acute Respiratory Distress Syndrome (ARDS): A Clinical Trial (INTACT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Adult patients (\> 18 years) with a diagnosis of acute lung injury, with viable GI function for enteral feeding~-~Exclusion Criteria: Patients who are (1) transferred from another ICU, (2) previously admitted to the ICU during the same hospitalization, (3) do not resuscitate status or \< 12 month perceived survival due to underlying disease state (4) severely immunosuppressed, (5) immobility prior to ICU admission, (6) documented neurological disease prior to admission. -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- intensive medical nutrition (Type: OTHER): participants will receive intensive medical nutrition from hospital admission to discharge
- control (Type: OTHER): participants will not receive intensive nutritional support from hospital admission to discharge

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria for the patients treated with antibiotics~* Adult patient hospitalized in a participating ward of the hospital for an expected duration of more than 24 hours.~* Treatment by ceftriaxone and / or a fluoroquinolone started by the attending physicians during hospitalization.~* No hospitalization or stay in nursing home in the previous three months.~* No use of antibiotics in the last 3 months~* Not receiving other antibiotics than ceftriaxone or FQ~* Informed consent~Inclusion criteria for the patients in the reference group~* Adult patient hospitalized in a participating ward of the hospital for an expected duration of more than 24 hours.~* Not receiving any antibiotic and not expected to receive any during hospitalization~* No hospitalization or stay in nursing home in the previous three months.~* No use of antibiotics in the last 3 months~* Informed consent~Exclusion criteria~* Pregnant or nursing women~* Patient who underwent colectomy or suffering from chronic intestinal disease (inflammatory intestinal disease or short bowel syndrome)~* Patient who used a bowel preparation solution for colonoscopy during hospitalization or in the previous week.~* Protected adult patient (deputyship or guardianship)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ceftriaxone (Type: None): Patients receiving a C3G (ceftriaxone) during the hospitalization.
- Ceftriaxone + Fluoroquinolone (Type: None): ceftriaxone followed by fluoroquinolone (which is a common situation in clinical practice, Fluoroquinolone being prescribed after obtaining antibiogram).
- Fluoroquinolones (Type: None): fluoroquinolones (levofloxacin, ofloxacin, moxifloxacin or ciprofloxacin).
- Reference (Type: None): A third reference group will consist of patients hospitalized in the same services as the case patients but did not receive antibiotics (60 patients). They will have an idea of possible changes in flora during hospitalization without any antibiotics, for example due to horizontal transfer of resistant strains. This group will be composed of 60 patients who had not received antibiotics within 3 months before and not receiving for the duration of their participation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Trial of the Intelon BOSS(TM) System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or older~2. Availability, willingness and sufficient cognitive awareness to comply with the examination procedures and schedule~3. Signed Written Informed Consent~Exclusion Criteria:~1. No light perception or low vision rendering the subject unable to fixate to keep gaze still enough to acquire images~2. Presence of corneal opacity~3. Presence of cortical cataracts visible in an undilated pupil~4. Any systemic disease or disorder which would prohibit image acquisition (e.g., Parkinson's Disease).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Imaging by BOSS System (Type: EXPERIMENTAL): Imaging by the BOSS System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female, age 18-45, COPD patients \> 40 years~* Healthy subjects and COPD patients; Provision of signed and dated, written informed consent prior to any study specific procedures~* Healthy subjects; Females must have a negative pregnancy test, must not be lactating and must be of non-child-bearing potential, by the following criteria: - irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy~* COPD patients; Females must have a negative pregnancy test, must not be lactating and must be of non-child-bearing potential, by the following criteria: Post menopausal. Woman below 50 years old will be considered post menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments, and with LH and FSH levels in the post menopausal range. Women over 50 years of age will be considered post menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment. - irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy~* Healthy subjects; Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg~* COPD patients; Have a body mass index (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg~Exclusion Criteria:~* Healthy subjects; Any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results of the subject's ability to participate in the study~* COPD patients; Any clinically significant disease or disorder (other than COPD) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results of the subject's ability to participate in the study~* Healthy subject and COPD patients; Any clinically significant abnormalities in clinical chemistry, haematology, urinalysis or physical examination results as judged by the investigator~* Healthy subject and COPD patients; Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): AZD9164
- B (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pre-operative Decitabine in Colon Cancer: a Proof of Principle Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
In- and exclusion criteria first part:~In order to participate in the first part of the study, five extra fresh biopsies to determine tumor methylation status, a subject must meet all of the following criteria:~Inclusion criteria:~1. Biopsy proven colon cancer or high suspicion of colon cancer on a previous endoscopy.~2. Planned endoscopy.~3. Age ≥ 18yr.~4. ECOG/ WHO performance 0-2.~5. Written informed consent.~Exclusion criteria:~1. Any psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol.~In- and exclusion criteria second part:~In order to participate in the second part of the study - treatment with decitabine - a subject must meet all of the following criteria:~Inclusion criteriä:~1. Patients with biopsy proven colon cancer who will undergo primary tumor resection.~2. Age ≥ 18yr.~3. ECOG/ WHO performance 0-2.~4. Adequate bone marrow function (ANC\>1500/mm3, hemoglobin\>9g/dL (which may be obtained by transfusions), platelets\>100,000)~5. Adequate hepatic function (AST and ALT \<2.5x upper limit of normal (ULN)).~6. Adequate renal function (Serum creatinine ≤1.5 x ULN or calculated creatinine of \>50ml/min)~7. Women of child-bearing age must be willing to use adequate contraception and have negative serum or urine pregnancy test within 3 days prior to registration.~8. Written informed consent.~Exclusion criteria:~1. Known hypersensitivity to decitabine or its additives.~2. Surgery not planned according to time frame of the study,~3. Other systemic or local treatment of the primary tumor in the waiting time until surgery.~4. Administration of any experimental drug within 60 days prior to the first dose of decitabine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine treatment (Type: EXPERIMENTAL): Treatment with decitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Skin and Blood Research Samples From Healthy Volunteers and Patients With Hematologic Diseases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18.~* No active systemic skin infection at biopsy site.~* No allergy to lidocaine or other local anesthetics~Exclusion Criteria:~ALL PATIENTS~* History of a bleeding disorder, easy bleeding, or bruising.~* Inability or unwillingness to provide informed consent.~SICKLE CELL PATIENTS~* Platelets ≤ 50,000~* INR ≥ 1.5~* Currently bing given intravenous heparin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy Volunteers (Type: OTHER): To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)
- Patients with benign, inherited hematologic disease (Type: OTHER): To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent and authorization of use and disclosure of protected health information~* Age 50 years or older~* Presence of subretinal hemorrhage (SRH) involving the fovea in patients with NVAMD including polypoidal choroidal vasculopathy (PCV)~Exclusion Criteria:~* SFH in the study eye due to causes other than NVAMD~* Media opacity due to concurrent vitreous hemorrhage or cataracts that preclude adequate imaging~* Substantial loss of VA due to condition other than AMD~* Limited visual potential from substantial atrophy or fibrosis in fovea~* Poor visual potential with known permanent reduction in visual acuity prior to SFH

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anti-VEGF injection only (Type: None): Patients who will receive monthly intravitreal anti-VEGF injection for 12 months, followed by anti-VEGF at standard of care treatment interval during months 12-24
- Hemorrhage displacement + Anti-VEGF (Type: None): Hemorrhage displacement (at investigators' discretion) followed by monthly intravitreal anti-VEGF injections for 12 months, and standard of care treatment interval during months 12-24

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven intermediate risk prostate cancer, which includes patients with any one of the following variables:~* Gleason 7 disease~* PSA 10-20 ng/ml~* Clinical T2b-T2c disease Note: Patients who only have radiographic evidence of T3 disease (i.e. extracapsular extension, or seminal vesical invasion radiographically) will not be excluded.~* Serum testosterone ≥ 240 ng/dL determined within 2 months prior to enrollment~* At least 4 weeks must have elapsed from major surgery~* KPS ≥ 80%~* Prostate size as determined on MRI to be \< 90 cc. Prostate size can be determined on CT scan if MRI is not available.~* 18 years of age or older~* IPSS ≤ 20~* Patient must be available for follow-up. After 2 years of follow-up following post-treatment biopsy, telephone-based follow-up will be acceptable~* Laboratory test findings within 8 weeks of randomization:~  * Adequate hepatic function with serum bilirubin ≤ 1.5 times the upper institutional limits of normal (ULN), ALT and AST ≤ 2.5 x ULN. Patients with a history of Gilbert's syndrome may be enrolled if the total bilirubin is \< 3 mg/dL with a predominance of indirect bilirubin~ * Adequate renal function with serum creatinine ≤ 1.5 x ULN~ * Adequate hematologic function with absolute neutrophil counts ≥ 1,500 cell/mm3 and platelets ≥ 100,000 cells/mm3 and hemoglobin value ≥ 9 g/dL (Note: patients whose anemia has been corrected to a hemoglobin value ≥ 9 g/dL with blood transfusions are allowed)~Exclusion Criteria:~* CT or MRI evidence of metastatic disease to the bone.~* Patients with one or more positive lymph nodes considered suspicious as determined by clinical assessment on MRI or CT~* Prior treatment for prostate cancer, including history of chemotherapy, hormonal therapy within 30 days of enrollment or surgery for prostate cancer (except for prior TURP or greenlight PVP which would be allowed)~* History of another malignancy within the previous 3 years except for the following: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, currently in complete remission, or any other cancer that has been in complete remission for at least 3 years~* Patients with Crohn's disease or ulcerative colitis

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degarelix in conjunction with stereotactic body radiosurgery (Type: EXPERIMENTAL): Degarelix monthly for 6 months SBRT 8 Gy x 5
- stereotactic body radiosurgery (SBRT) (Type: EXPERIMENTAL): SBRT 8 Gy x 5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:~1. Male or non-pregnant female (if female, either post-menopausal, or if of child-bearing potential, using adequate contraception e.g. hormonal or barrier methods, or surgically sterile, and not lactating)~2. Age \>/= 18 years of age~3. Present or prior history of symptoms of heart failure (dyspnea, fatigue) consistent with diagnosis of diastolic heart failure, following optimized medical therapy including blood pressure control with ACE inhibitors and/or beta-blockers for 2 weeks or over.~4. Echocardiographic evidence of preserved left ventricular systolic function (LVEF \>/= 45%) and evidence of diastolic dysfunction (by transmitral inflow, pulmonary venous flow, color M-mode and/or tissue Doppler).~5. Signed informed consent~Exclusion Criteria:~The presence of any of the following will exclude a patient from study enrollment:~1. Unwilling to participate for the 9-month duration of the study~2. Significant primary valvular, pulmonary or congenital cardiac disease believed to be the cause of dyspnea~3. Life expectancy or planned cardiac transplantation \<9 months~4. History of hypertrophic obstructive cardiomyopathy~5. Unstable angina or ischemia requiring revascularization~6. Renal insufficiency (Cr \>2.0 mg/dL in males and \>1.8 mg/dl in females, or modified Cockcroft-Gault estimate of creatinine clearance \<30 mL/min) at enrollment~7. Known hypersensitivity to spironolactone or eplerenone~8. Decompensated heart failure or clinical evidence of instability at the time of enrollment 9 History of hyperkalemia (\>6.0 mg/dL) with spironolactone~10. Use of spironolactone or amiloride within 30 days 11. Poorly controlled seating blood pressure at the time of drug initiation:~* Systolic blood pressure \>160 mmHg; and/or~* Diastolic blood pressure \>100 mmHg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eplerenone (Type: ACTIVE_COMPARATOR): Eplerenone 25mg daily for 2 weeks Titrated to Eplerenone 50mg daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo dosed daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged 18 years and over~2. Planned surgical resection of NSCLC, stage IB ≥ 4 cm, II or IIIA according to the 8th edition of TNM classification16.~   1. Cohort #1: Neoadjuvant Therapy - For patients who will receive neoadjuvant therapy, enrollment occurs prior to the initiation of treatment. Patients undergoing neoadjuvant therapy who achieved tumor reduction, are eligible based on baseline radiographic staging.~  2. Cohort #2: Pre-Surgery - For patients identified prior to planned surgical resection, enrollment occurs within 30 days of the planned surgery. Eligibility is based on surgical pathology.~  3. Cohort #3: Post-Surgery - For patients identified post-surgical resection, enrollment occurs prior to the initiation of adjuvant therapy. Eligibility is based on surgical pathology.~3. Patients with positive margins and those requiring adjuvant radiation therapy are eligible.~4. Patients with a secondary malignancy that was treated with curative intent and without evidence of relapse for at least 5 years.~5. Willingness to undergo all study collection procedures and follow up.~6. Provision of written informed consent~Exclusion Criteria:~1. Male or female aged less than 18 years~2. NSCLC disease other than stated above~3. Patients with a secondary malignancy that was not treated with curative intent or has had a disease relapse in the past 5 years.~4. Unwilling to undergo all study collection procedures and follow up.~5. Unable or unwilling to provide consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SEMPERFLO* Pain Management System in Inguinal Hernia Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a candidate for primary, non-emergent unilateral, open inguinal hernia repair procedure~* Subject is 18 years or older~* Subject must be willing to participate in the study, and provide informed consent to participate.~Exclusion Criteria:~* Subjects undergoing recurrent hernia repair;~* Subjects who plan to undergo another elective surgical procedure prior to the completion of this study;~* Subjects with known allergy to bupivacaine;~* Subjects with immunodeficiency diseases (including known HIV);~* Subjects with any findings identified by the surgeon that may preclude conduct of the study;~* Subjects who are known current alcohol and/or drug abusers;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SEMPERFLO Pain Management System (Type: EXPERIMENTAL): None
- ON-Q PainBuster Post-Op Pain Relief System (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility